Back

Interactive case-based education significantly improves competence in diagnosing transthyretin cardiac amyloidosis

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease - hypertrophic cardiomyopathy (2) Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Christy Rohani-Montez

Medscape Education Global, London (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Recognizing red flags: don't judge a book by its cover. data from a multicentric nationwide study
Doctor A. Pinho (Porto, PT)
Abstract Slides Video
Presentation thumbnail
Mavacamten use in a real-world cohort of obstructive hypertrophic cardiomyopathy patients: insights from the initial centre experience
Doctor M. Lima (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Estimating hypertrophic cardiomyopathy genotype pre-test probability: an online calculator
Mr P. Kopp (Stony Brook, US)
Abstract Slides Video
Presentation thumbnail
Differentiating clinical trial endpoints in transthyretin cardiac amyloidosis is significantly improved with continuing medical education
Doctor C. Rohani-Montez (London, GB)
Abstract Slides Video
Presentation thumbnail
Effect of TTR stabilisers on strain values derived by echocardiography in patients with wild type ATTR Amyloidosis
Doctor J. Westphal (Jena, DE)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in myocardial disease - hypertrophic cardiomyopathy (2)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Medical education significantly improves the recognition of red flags of transthyretin cardiac amyloidosis
thumbnail
Congress Presentation
Understanding the patient burden in transthyretin cardiac amyloidosis is significantly improved with continuing medical education
thumbnail
Congress Presentation
Differentiating clinical trial endpoints in transthyretin cardiac amyloidosis is significantly improved with continuing medical education

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources